Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**68Ga-DOTA-D-Alanine-BoroPro** is an experimental **gallium-68-labeled fibroblast activation protein imaging radiopharmaceutical** developed as a PET tracer for visualization of **fibroblast activation protein** expression in malignant and non-malignant tissues. It is a DOTA-conjugated derivative of D-Alanine-BoroPro, a boronic acid-based FAP inhibitor scaffold, radiolabeled with gallium-68 for positron emission tomography. Preclinical work and first-in-human imaging reported specific recognition of FAP, rapid renal clearance, and imaging activity in glioblastoma, breast cancer, prostate cancer, and myocardial infarction, supporting its development as a targeted molecular imaging agent rather than a therapeutic drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-DOTA-D-Alanine-BoroPro.